Alto Neuroscience, Inc. (NYSE: ANRO) is a Healthcare company (Biotechnology) with a market capitalization of $999M. The Maz Rating grades it against the other companies in its sector.
Alto Neuroscience, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $24.91, Alto Neuroscience, Inc. trades at 3.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -41.8%, return on invested capital of 10.2% and a free cash flow yield of -8.0%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 18.12. Over the past 52 weeks the share price ranged from $12.51 to $37.48, with a beta of 1.16.
Alto Neuroscience, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Alto Neuroscience, Inc. (ANRO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.10% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.1% / 30% · Interest income / Revenue 260000000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 1.10% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 26.1% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 260000000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 1.10% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 26.1% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 260000000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 4.45% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.3% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 260000000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 4.13% / 33.33% · (Cash+ST Inv) / Total Assets 97.8% / 33.33% · (Cash+Recv) / Total Assets 97.8% / 33.33% · Interest income / Revenue 260000000.0% / 5% | Fail |
No. As of September 2026, Alto Neuroscience, Inc. (ANRO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Alto Neuroscience, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 260000000.0% of each dividend: Alto Neuroscience, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.